chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The MA administered 0.3ml of undiluted pediatric Covid vaccine and administered to patient.  She had meant to administer the bivalent booster.  No adverse reaction reported.
24 hours after receiving vaccine patient was noted by mom to have warmth, tenderness, and induration at site of varicella injection on posterior left arm. 48 hours patient cam in, and where injection was given, erythema 65x40mm, induration 25x30mm, located posterior left upper arm
where the syringe hub of the Typhim broke and caused an injury; Initial information received on 26-Apr-2022 regarding an unsolicited valid  non-serious case received from a consumer/non-hcp.  This case involves an unknown age and unknown gender patient who experienced where the syringe hub of the typhim broke and caused an injury while receiving vaccine TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI].   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received a  dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE lot number not reported via unknown route and expiry date in unknown administration site for Immunisation.  On an unknown date the patient developed a non-serious where the syringe hub of the typhim broke and caused an injury (injury) (unknown latency) following the administration of TYPHOID VI POLYSACCHARIDE VACCINE.  Action taken with TYPHOID VACCINE (TYPHIM VI) was not applicable.  It was not reported if the patient received a corrective treatment for the event (where the syringe hub of the Typhim broke and caused an injury).  At time of reporting, the outcome was Unknown for the event where the syringe hub of the typhim broke and caused an injury.
Patient taken to designated area to be assessed and observed.  Vital signs obtained and blood pressure noted to be 80/50 and patient lowered to floor at this time and feet elevated. Blood pressure retaken after 5 minutes and noted to be 120/80 and showing improvement. HR 88 and oxygen noted to be 99% on RA. 10: 17 Vital signs 140/82 HR 100 oxygen 99%. Patient consumed water as requested and tolerating well. 11:09: 140/90 oxygen 99% HR 88 and RR 18. Patient having c/o chest tightness that is not improving at this time. Patient states that he feels a lot better but no improvement with chest tightness. Observation reviewed with staff and decision made to call out to 911 at 11:28.  Prior to rescue team arriving vital signs set to be monitored every 15 minutes starting at 1132. 1st set noted to be 110/88 HR 81 oxygen at 100% RA RR 18. 11:44 Rescue team arrived on scene and report provided and patient care given to them at this time. Patient's mother arrived at scene and made aware of condition and rescue decision.
Patient arm 2 inches below inj site became red and hot and painful. Patient saw physician and was given Doxycycline for cellulitis. After 2 to 3 days the arm was much improved.
This spontaneous report was received from a medical assistant and refers to a 6 day old patient of unknown gender. The patient's pertinent medical history, drug reactions or allergies and concomitant therapies were not reported. On 23-AUG-2017, the patient was vaccinated with improperly stored VARIVAX injection, (lot # N007930 with expiration date on 08-MAR-2018, dose, anatomical location and route not reported) for prophylaxis (drug administered to patient of inappropriate age), reconstituted with properly stored sterile diluent (manufacturer unknown) (lot# N013282 with expiration date 23-AUG-2019). The administered vaccine experienced a temperature excursion of 6 degree Fahrenheit to 14 degree Fahrenheit for 18 hours. There was no previous temperature excursion and the call was not because of a data logger. No adverse effects were reported. This is one of the several reports received from the same reporter.; Sender's Comments: US-009507513-1709USA001401: US-009507513-1710USA008702: US-009507513-1709USA000870:
has a cold sore; This spontaneous case was reported by a consumer and describes the occurrence of ORAL HERPES (has a cold sore) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included ACYCLOVIR [ACICLOVIR] for an unknown indication.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced ORAL HERPES (has a cold sore). At the time of the report, ORAL HERPES (has a cold sore) outcome was unknown.       The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.    Reporter did not allow further contact; Sender's Comments: Although a temporal association exist, based on the information provided, it cannot be determined if the event was pre-existing or started after vaccination  Event was reported one day after vaccine administration. Additional information has been requested
Patient was standing in room after administration talking with MA and joking with MA. Patient not dizzy or light headed. MA left to get paperwork for patient. MA heard patient asking for help and found her in the hallway with bloody mouth and had become incontinent of urine. Patient had no recollection of what happen.
Fever, chills, fatigue, headache; redness, swelling and pain at injection site
Got Moderna booster 3 months after Pfizer booster; This spontaneous case was reported by a pharmacist and describes the occurrence of EXTRA DOSE ADMINISTERED (Got Moderna booster 3 months after Pfizer booster) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer (First dose) on 08-Mar-2021, pfizer (2nd shot) on 29-Mar-2021 and pfizer (Booster) on 21-Oct-2021. Past adverse reactions to the above products included No adverse event with Pfizer, pfizer and pfizer. Concurrent medical conditions included Diabetes.    On 05-Jan-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 05-Jan-2022, the patient experienced EXTRA DOSE ADMINISTERED (Got Moderna booster 3 months after Pfizer booster). On 05-Jan-2022, EXTRA DOSE ADMINISTERED (Got Moderna booster 3 months after Pfizer booster) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The concomitant medications were not reported. The treatment information was not provided.   Patient was not immunocompromised
Immediately pale and lightheaded after injection, passed out in chair, lowered to floor, woke up feeling nausea, moved ia stretcher. Vitvals obtained and monitored. Per on site physician - severe vasovagal reaction - resolved. pt released at 3:32 with husband. Vitals as follows: LYING 3:05 - HR 98, Resp 14, BP 127/86, Sp02 100 LYING 3:15 - HR 89, Resp 12, BP 127/86, Sp02 100 SITTING 3:27 - HR 75, Resp 12, 122/85, Sp02 100
A non-serious spontaneous report of expired FLUMIST administered was received from a health professional concerning a 44-month-old female. Neither medical history nor concomitant medication was reported for this patient. The FLUMIST expired on 29-Nov-2010. On 29-Dec-2010, the patient received expired FLUMIST. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved. This case will be submitted in accordance with MedImmune's FLUMIST post-marketing commitment for the indicated population of 2 years to 59 months of age. Additional information received on 09-Mar-2011 and incorporated into case: no late occurring adverse events.
Little red spot here and there; He woke up with itching all over; This is a spontaneous report from a contactable consumer. A 75-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL9261), via an unspecified route of administration on 21Jan2021 at 0.3 mL, single for COVID-19 immunization. Medical history included Heart disease, Diabetes, Atrial fibrillation (AFib), Gastrooesophageal reflux disease (GERD), shellfish allergy, heart surgery, quadruple bypass, allergic reactions and hives. Concomitant medications included apixaban (ELIQUIS) for AFib, clopidogrel bisulfate (PLAVIX) as blood thinner, metformin hydrochloride (METFORMIN ER) for Diabetes, Atorvastatin, Metoprolol Succinate (ER), pantoprazole sodium sesquihydrate (PROTONIX) for GERD, and Losartan potassium to protect kidneys from diabetes. The patient had an anaphylactic shock reaction in past and requires an epi pen for the past 30 years but was unsure what he was allergic to. During his allergic reactions, he usually has hives but with this reaction he has no hives, no difficulty. The patient got the Pfizer vaccine (COVID-19 Vaccine) on 21Jan2021, last Thursday. He had no symptoms, no problems that evening. The next night at 1 in the morning he woke up with itching all over. He took some Benadryl and did not go away. Took a little more Benadryl, finally he was up about 2 hours with this itching and then he went to bed and slept quite a while because he had taken Benadryl. The next day he seemed okay, during the day. Then again during the night at 1 'O clock or so he then woke up again with itching all overtook Benadryl again. So, that was on Saturday night. So, Friday night, Saturday night and then Sunday he had the same thing again. The doctor stated that it has been 3 days of itching, so he put him on Medrol Dosepak which the patient got today, so he has just started that. Previously, 30 years ago, he had anaphylactic shock and they were never able to figure out exactly ran all kind of tests, never found out what exactly was he had the allergic reaction to. He had in the past but not quite a few years now. He would kind of just break out in hives and that. But during this time he really did not get hives, he got today 25Jan2021 a little red spot here and there, that he would be itching. He has no red spots or anything by the site of the injection but there is concern that now he has got to take a Medrol Dosepak (treatment) and kind of hopefully not wake up again tonight with this itching. So, the concern is the next shot. The patient's weight was "199, 200 pounds" (Reporter was not sure). The outcome of the events was unknown.
38 y/o male who received his seasonal flu shot in his left upper arm on Sat, 2 FEB at week-end drill. That was the only vaccine he received that day. He did not note anything unusual about vaccine site, but reports prior to vaccine administration, Immunizer changed the needle. On Sunday night (post-vaccine day 1), patient noted that his left axillary area was sore. He reported mild tenderness at the vaccination site, but nothing out of the ordinary. By Monday, patient said his left axillary area was red, swollen and tender, which increased over the next two days. On Wed, 6 FEB (post-vaccine day 4), the area was swollen to the size of a "grapefruit" and really sore. Patient has no systemic symptoms, other than some nasal congestion. His axillary area is not pruritic, warm or hard/firm to touch, and has no drainage. He denies any trauma or bites to that arm. Not aware of any other potential exposures. No sore throat or swollen glands in neck or above clavicle. Denies weakness and numbness/tingling of his LUE. Patient denies angioedema, hives/rashes, swelling of mouth and throat, cardiovascular, respiratory, and GI symptoms. He has not self treated except for a TYLENOL last night. He denies significant PMH and denies a hx of abscesses or boils. He is on no meds and has no allergies, but reports N/V/D after taking codeine. No previous vaccine reactions with past flu shots or other vaccinations. Follow up on 7 FEB: Contacted patient by phone this afternoon. He reports his left axillary pain increased last p.m. and radiated to his left shoulder. Pain was made worse with LUE movement. Patient received a steroid injection at Urgent Care and reports almost complete resolution of left axillary and shoulder symptoms today.
Patient felt a little nausea, then he appeared to lose consciousness for about 1 to 2 minutes and was slouched over. He recovered, and after a few minutes he felt fine. He left the facility with no other adverse affects.
Wed: PPD placed Thurs: Fever no other sx. Fri: Night terrors
FLUL LIKE SYMPTOMS SINCE 3AM 1/8/2021, CHILLS, SEVERE MUSCLE PAIN BACK NECK AND HEAD, HOT FLASHES, LOSS OF APPETITE , PAIN AT VACCINATION SITE, LEFT AXILLARY PAIN ON ABDUCTION. UNABLE TO GO TO WORK DUE TO SYMPTOMS
After giving patient her three injections, 10 minutes from the last shot, patient experienced light-headedness, nausea, tunnel vision and cold and clammy and cyanosis of lips.  Let patient lie down. Gave patient cheesy crackers and water. Patient did state, she did not have anything to eat or drink at all this morning. Patients color came back to normal. Took patients vital signs, HR 101; O2 98%; BP 98/60. Patient began to feel better. Patient stayed for 15 minutes . Began to get patient up nice and slow. Patient did not complain of any dizziness or nausea. Let patient stand up after sitting up for a few minutes. Patient stated she was okay and feeling much better. Walked patient and her mom down to main level of the hospital. Patient stated again, she was okay.
This is a spontaneous report from a contactable consumer. A male patient of an unspecified age received TRUMENBA intramuscular at 0.5 ml single on an unspecified date in Mar2015. Relevant medical history and patient concomitant medications were not reported. The patient experienced headache at 4 pm on the day of the vaccination. No investigations were performed, no treatment was given for the reported event. The headache was lasting for over 18 hours and the patient was not recovered at the time of this report. Follow-up (14MAY2015): Follow-up attempts completed. No further information expected.
Pt developed localized erythema on upper arms bilat and HEENT. Erythema clearing. No difficulty breathing, generalized itching, bp 104/70, warm to touch, bp 20 later 100/62
swelling, redness, warmth, itching.  Treated with second generation anti-histamine and topical corticosteroid. have not assessed reponse to treatment yet.  felt uncomfortable after injection, then worse next day.
Occasional discomfort; Itching at the rash site; Pinkish/reddish circular rash around the injection site; pinkish/reddish circular rash around the injection site; This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (Occasional discomfort), VACCINATION SITE PRURITUS (Itching at the rash site), VACCINATION SITE RASH (Pinkish/reddish circular rash around the injection site) and VACCINATION SITE ERYTHEMA (pinkish/reddish circular rash around the injection site) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010a27a) for COVID-19 vaccination.     The patient's medical history was not provided.  Concomitant products included ROSUVASTATIN, VITAMIN D NOS, VITAMIN B COMPLEX (B COMPLEX (B50)), FISH OIL (OMEGA 3 FISH OIL [FISH OIL]) and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (Itching at the rash site), VACCINATION SITE RASH (Pinkish/reddish circular rash around the injection site) and VACCINATION SITE ERYTHEMA (pinkish/reddish circular rash around the injection site). On an unknown date, the patient experienced DISCOMFORT (Occasional discomfort). At the time of the report, DISCOMFORT (Occasional discomfort), VACCINATION SITE PRURITUS (Itching at the rash site), VACCINATION SITE RASH (Pinkish/reddish circular rash around the injection site) and VACCINATION SITE ERYTHEMA (pinkish/reddish circular rash around the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient did not take any treatment for events.
Site reaction - induration, erythema. More concerning - asthma exacerbation. Patient well controlled previously on ICS/LABA and Fasenra injections. Wheezing, short of breath, sense of throat swelling.
Exactly 12 hours after HPV injection, vomiting, diarrhea, severe stomach pains, severe headache, chest pain, skin rash, tingling tongue.
Swollen and sore left armpit, center of chest is sore, mild headache, lethargic
Supraventricular tachycardia (heart rate of 180-190) requiring ER visit on 16 October 2022 and administration of adenosine to return to normal sinus rhythm. SVT occurred again after the 4th dose of Moderna (2nd booster) in April, 2022, but was returned to NSR with valsalva maneuver by me and did not require medical intervention. This 4th dose was 1/2 of the first 3 doses.
PATIENT WAS TEARING; SWOLLEN EYES, WORSE LEFT EYE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1805022, and batch number: 1805022 expiry: UNKNOWN) .5 ml, administered on 06-MAR-2021 to Left Arm for prophylactic vaccination. Concomitant medications included hydroxyzine. On 07-MAR-2021, the subject experienced swollen eyes, worse left eye. On an unspecified date, the subject experienced subject was tearing. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from swollen eyes, worse left eye, and the outcome of patient was tearing was not reported. This report was non-serious.
Sleepiness; Headache; Joint pain; Injection pain; High fever; Chills; This is a spontaneous report from a contactable nurse. A 57-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE ; Lot Number: ER8732; Expiration Date: 30Jun2021), via an unspecified route of administration on 27Mar2021 (at the age of 57-years-old) at dose 1, single for covid-19 immunization. The patient medical history were not reported. Patient take a number of medications. The patient experienced sleepiness, headache, joint pain, injection pain, high fever, chills on an unspecified date. Patient has been taking Tylenol and that helping for the events. The outcome of the events was unknown. The relationship between the vaccine and events was related.  No follow-up attempts are possible. No further information is expected.
Irritation throat, pain throat, body aches, fever, cough with salty clear sputum
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose02/15/21 2nd dose03/08/21 Diagnosed covid positive:08/20/21 Symptom onset: Exposure: Symptoms:Asymptomatic
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 48-year-old male patient received BNT162b2 (BNT162B2), on 01Feb2022 at 07:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 47 years, in left arm for covid-19 immunization; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history included: "Crohn's disease" (unspecified if ongoing), notes: Other medical history: Crohn's disease; Breast Cancer; "Breast Cancer" (unspecified if ongoing), notes: Other medical history: Crohn's disease; Breast Cancer. Concomitant medication(s) included: SYNTHROID; TAMOXIFEN. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (28Jul2022) Negative, notes: Finished five day course, tested negative for five days after; (29Jul2022) positive, notes: Tested positive on day six. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient received other medication in 2weeks (Synthroid, Tamoxifen).  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 21-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant and treatment medications were reported. No adverse reactions were reported by patient.
Pt recived his second Moderna vaccine 2/15/21, and on 2/16, staff at pt's group home noted pt was unable to walk although pt previously ambulatory (could go on long hikes prior to acute illness). Pt was grabbing his legs and rubbing them, and initially staff thought it was pain that would resolve.  However, on 2/22, lower extremity edema was noted, and pt without improving symptoms, so he was brought to the hospital for evaluation and treatment. GBS suspected, IVIG initiated.
approx 2hrs p/vax pt exp headache, nausea, sore abdomen, tiredness, achy bones & diarrhea.
Fatigue and aches that started a few hours later and lasted about 36 hours total. Muscle aches where specifically in the injection arm, neck, shoulders, and back.
My left armpit has a huge, swollen gland. The injection site is still pretty sore, too.
A report was received from a health care professional on 13 November 2003 concerning an unspecified number of vaccinees less than 4 years who inadvertently received Fluvirin on an unspecified date. On an unspecified date the vaccinees inadvertently received Fluvirin. No adverse symptoms were reported at the time of reporting. There was insufficient information to determine the reporter's causality assessment. Follow up pending.
HBV & VZV given at 2 PM on 04/12/2001. In the AM of 04/13/01, the patient had swelling, erythema, and bullae noted on the right triceps, site of VZV vaccine. Area appears cellulitis.